Frankfurt (Germany), Basildon (United Kingdom), August 8, 2019 – Funds advised by Triton have successfully completed the acquisition of a majority stake of Atnahs, a specialty pharmaceutical business, focussed on the acquisition, development and marketing of mature branded medicines. Terms and conditions of the transaction are not disclosed.
About Atnahs
Atnahs is a specialty pharmaceutical business, focused on acquiring mature branded medicines out of large cap and specialty pharma companies and developing its own niche medicines. Atnahs operates a portfolio of over 800 SKUs across more than 130 markets.
About Triton
Founded in 1997 and owned by its partners, Triton Partners is a leading European mid-market sector-specialist investor. Triton Partners focuses on investing in businesses that provide mission critical goods and services in its three core sectors of Business Services, Industrial Tech, and Healthcare.
Triton Partners has over 150 investment professionals and value creation experts across eleven offices and invests through three complementary “All Weather” strategies: Mid-Market Private Equity, Smaller Mid-Cap Private Equity, and Opportunistic Credit.